Lederle aimed to create a drug that was less cardiotoxic than anthracyclines. They didn't consider that Zan's surprising lack of cardiotoxicity was due to its cardioprotection MOA.
RAC media coverage, page-1897
-
- There are more pages in this discussion • 397 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.68 |
Change
-0.020(1.18%) |
Mkt cap ! $286.3M | |||
| Open | High | Low | Value | Volume |
| $1.69 | $1.69 | $1.65 | $91.80K | 55.06K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 337 | $1.68 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.69 | 600 | 1 |
View Market Depth
| Last trade - 15.22pm 18/09/2024 (20 minute delay) ? |
| RAC (ASX) Chart |